[Latest] Global Breast Cancer Therapeutics Market Size/Share Worth USD 66.1 Billion by 2033 at a 6.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 06, 2024 08:30 ET
|
Custom Market Insights
Austin, TX, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Breast Cancer Therapeutics Market Size, Trends and Insights By Type of Therapy...
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
November 02, 2023 10:37 ET
|
Onconova Therapeutics, Inc.
Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 (GLOBE...
Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference
December 07, 2022 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference
November 28, 2022 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference
September 22, 2022 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics Announces Acceptance of Abstract for Publication at the ASCO Annual Meeting
April 27, 2022 10:17 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics Announces the Appointment of Mark Gelder, M.D., as Chief Medical Officer
June 01, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 01, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor
March 25, 2019 07:00 ET
|
Cyclacel
-- PALOMA-3 study gene expression profiling shows that CDK2 is a key kinase bypass mechanism after treatment with palbociclib plus hormone therapy -- -- Cyclin E is proposed as the first predictive...